Oxybuprocaine Hcl
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00892 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 30 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | irritable bowel syndrome | KG + DL |
| 2 | dermatitis | KG + DL |
| 3 | acrodermatitis chronica atrophicans | KG + DL |
| 4 | neonatal dermatomyositis | KG + DL |
| 5 | panuveitis (disease) | KG + DL |
| 6 | iris disease | KG + DL |
| 7 | bronchitis | KG + DL |
| 8 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | KG + DL |
| 9 | hydroa vacciniforme, familial | KG + DL |
| 10 | amyopathic dermatomyositis | KG + DL |
| 11 | acne keloid | KG + DL |
| 12 | filariasis | KG + DL |
| 13 | abnormal pupillary function (disease) | KG + DL |
| 14 | benign neoplasm of iris | KG + DL |
| 15 | isolated iridoschisis | KG + DL |
| 16 | iris cancer | KG + DL |
| 17 | ciliary body disease | KG + DL |
| 18 | ciliary body neoplasm | KG + DL |
| 19 | neuromuscular junction disease | KG + DL |
| 20 | cauda equina syndrome | KG + DL |
| 21 | uveitis | KG + DL |
| 22 | ciliary body cancer | KG + DL |
| 23 | benign neoplasm of ciliary body | KG + DL |
| 24 | pulverulent cataract | KG + DL |
| 25 | iris neoplasm | KG + DL |
| 26 | congenital myasthenic syndrome with tubular aggregates | KG + DL |
| 27 | pupil disease | KG + DL |
| 28 | cataract - microcornea syndrome | KG + DL |
| 29 | seborrheic dermatitis | KG + DL |
| 30 | myasthenia, congenital, refractory to acetylcholinesterase inhibitors | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.